Oxurion NV - ESG Rating & Company Profile powered by AI
This article includes a Q&A section about Oxurion NV. The report of Oxurion NV is prepared by All Street Sevva using leading artificial intelligence. If you are employed by Oxurion NV and you would like to licence your ESG rating, please get in touch.
Oxurion NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 5.3, social score of 1.6 and governance score of 2.0.
3.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1309 | Willow Biosciences Inc | 3.1 | Medium |
| 1309 | biOasis Technologies Inc | 3.1 | Medium |
| 1336 | Oxurion NV | 3.0 | Medium |
| 1336 | BridgeBio Pharma Inc | 3.0 | Medium |
| 1336 | Absci Corp | 3.0 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Oxurion NV have an accelerator or VC vehicle to help deliver innovation?
Does Oxurion NV disclose current and historical energy intensity?
Does Oxurion NV report the average age of the workforce?
Does Oxurion NV reference operational or capital allocation in relation to climate change?
Does Oxurion NV disclose its ethnicity pay gap?
Does Oxurion NV disclose cybersecurity risks?
Does Oxurion NV use carbon offsets or credits exclusively for residual emissions (typically less than ~0.5–5% of total emissions)?
Does Oxurion NV offer flexible work?
Does Oxurion NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Oxurion NV disclose the number of employees in R&D functions?
Does Oxurion NV plan to change its portfolio composition to lower the emissions intensity of its energy mix (e.g., by shifting from oil to gas, or by adding lower-carbon options like hydrogen, e-fuels, bioenergy, etc.)?
Does Oxurion NV conduct supply chain audits?
Does Oxurion NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Oxurion NV conduct 360 degree staff reviews?
Does Oxurion NV disclose the individual responsible for D&I?
Does Oxurion NV disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Oxurion NV disclose current and / or historical scope 2 emissions?
Does Oxurion NV disclose water use targets?
Does Oxurion NV have careers partnerships with academic institutions?
Did Oxurion NV have a product recall in the last two years?
Does Oxurion NV disclose incidents of discrimination?
Does Oxurion NV allow for Work Councils/Collective Agreements to be formed?
Has Oxurion NV issued a profit warning in the past 24 months?
Does Oxurion NV disclose parental leave metrics?
Does Oxurion NV disclose climate scenario or pathway analysis?
Does Oxurion NV disclose current and / or historical scope 1 emissions?
Does Oxurion NV explicitly state that carbon offsets or credits are separate from its emissions-reduction progress or that they are not counted toward its emissions-reduction targets?
Are Operating Expesnses linked to emissions reduction?
Does Oxurion NV disclose the pay ratio of women to men?
Does Oxurion NV support suppliers with sustainability related research and development?
Does Oxurion NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Oxurion NV reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Oxurion NV involved in embryonic stem cell research?
Does Oxurion NV disclose GHG and Air Emissions intensity?
Does Oxurion NV disclose its waste policy?
Does Oxurion NV report according to TCFD requirements?
Does Oxurion NV plan to mitigate emissions from future new production assets through measures such as electrifying equipment, carbon capture and storage, repurposing waste gas, methane leak detection and repair, eliminating flaring, etc.?
Does Oxurion NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Oxurion NV disclose energy use targets?
Does Oxurion NV disclose its Renewable Energy targets?
Are emissions metrics verified by STBi?
Does Oxurion NV have a policy relating to cyber security?
Potential Risks for Oxurion NV
These potential risks are based on the size, segment and geographies of the company.
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.